ANTIBODY DISCOVERY PLATFORM

Driving next-generation antibody leads to clinical success
Mabqi is committed to delivering highly developable and functional human antibodies-based leads in various therapeutic applications and areas such as oncology, autoimmune and inflammatory diseases, …
Our tailored and integrated solution is designed to:
- Accelerate antibody discovery & development timelines
- Maximize potential therapeutic valuable lead candidates
- Provide robust, reliable scientific results
- Deliver highly developable and functional human antibodies lead candidates.
Our team has demonstrated its commitment to excellence and collaboration through more than 30+ antibody discovery programs.

Our solution
Mabqi has developed a cutting-edge antibody discovery platform combined to its proprietary human synthetic antibody suite of libraries and outstanding scientific know-how.
We leverage on customized antibody screening programs using our proprietary Human Synthetic Antibody Libraries (HuscI2TM, FabIgTM, pHuscI2TM) and highly innovative, flexible, and robust processes.
Our approach enables in vitro selection of robust and stable antibodies that bind to target antigen with high specificity. This approach is suited for virtually any targets including ion channels, GPCRs, peptides, proteins, peptide-MHC complexes,… It works effectively regardless of the antigen’s form or environment, whether it’s a protein, cell, or peptide. Importantly, this technique eliminates the need for animal immunization.
Our versatile platform excels in addressing complex programs by seamlessly integrating multiple requirements. This adaptability allows us to tackle a wide array of specifications, including:
- Target specificity
- Multi-species cross-reactivity
- Agonist /antagonist properties
- Enzyme inhibition capabilities
- pH sensitivity
Antibody discovery platform

Our expert team provides comprehensive solutions for antibody discovery and development programs, delivering seamless support across the entire discovery workflow.
- Optimal antibody selection strategies based on:
- Ready-to-use fully human synthetic libraries suite (HuscI2™, pHuscI2™)
- Advanced screening workflow: AI-powered phage and yeast display technologies
Bio-panning strategies are performed on proteins, peptides, cells, liposomes, VLPs, …
The combination of phage and yeast display takes advantage of both platforms by starting with a vast number of antibodies in the phage display selections followed by yeast display to refine and select a diverse population of high-affinity binders (cross-reactivity, additional specificity or requested characteristics).
- Comprehensive antibody hits’ characterization
- Rigorous functional validation processes: internalization assays, direct cytotoxicity assays, ….
Further reformatting to IgG, BsAb, ADC formats can be performed with additional in-depth profiling of antibodies.
Our antibody discovery platform delivers fully human antibody unique hits with :
- proven and highly developable human antibody frameworks across Fab, scFv, scaffolds
- high diversity (10E11 clones)
- high affinity and improved characteristics such as species cross reactivity, pH-sensitivity, internalization, … .